A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MK-6194 in Adult Participants With Systemic Lupus Erythematosus
Latest Information Update: 24 Aug 2024
At a glance
- Drugs MK 6194 (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions; Therapeutic Use
- Acronyms MK-6194-006
- Sponsors Merck Sharp & Dohme
- 03 May 2024 Planned End Date changed from 10 Jun 2027 to 9 Jul 2027.
- 04 Jan 2024 Status changed from not yet recruiting to recruiting.
- 29 Nov 2023 Status changed from planning to not yet recruiting.